Literature DB >> 14512308

VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13.

Koichi Kokame1, Masanori Matsumoto, Yoshihiro Fujimura, Toshiyuki Miyata.   

Abstract

ADAMTS-13 was recently identified as a new hemostatic factor, von Willebrand factor (VWF)-cleaving protease. Either congenital or acquired defects of the enzymatic activity lead to thrombotic thrombocytopenic purpura (TTP). ADAMTS-13 specifically cleaves a peptidyl bond between Y1605 and M1606 in the A2 domain of VWF. Here, we determined the minimal region recognized as a specific substrate by ADAMTS-13. A series of partial deletions in the A2 domain flanked with N- and C-terminal tags were expressed in Escherichia coli and affinity-purified. These purified proteins were incubated with human plasma, subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and analyzed by Western blot. Judging from mobility shifts, all constructs except one were cleaved at the expected site. Data suggested that a minimal region as a functional substrate consisted of 73 amino acid residues from D1596 to R1668 of VWF, designated VWF73, and that further deletion of the E1660-R1668 region led to the loss of cleavage by ADAMTS-13. VWF73 was not cleaved by plasma from patients with congenital or acquired TTP, but cleaved by plasma from patients with hemolytic uremic syndrome, suggesting that VWF73 is a specific substrate forADAMTS-13. Thus, VWF73 will be a useful seed to develop a new rapid assay to determine ADAMTS-13 activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512308     DOI: 10.1182/blood-2003-08-2861

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

2.  Von Willebrand factor antigen and ADAMTS13 activity assay in pregnant women and severe preeclamptic patients.

Authors:  Dandan Zhang; Juan Xiao; Haoliang Huang; Juanjuan Chen; Tao Liu; Zongzhi Yin; Danping Gao; Qiong Liu; Jihui Ai; Suhua Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

3.  The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Authors:  Jihui Ai; Paula Smith; Shuwei Wang; Ping Zhang; X Long Zheng
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

4.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

Review 5.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

6.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 7.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

8.  Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.

Authors:  Jeffrey J Sutherland; Lee A O'Brien; David Lillicrap; Donald F Weaver
Journal:  J Mol Model       Date:  2004-08-03       Impact factor: 1.810

Review 9.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

10.  Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.

Authors:  Kenji Nishio; Patricia J Anderson; X Long Zheng; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.